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Introduction of the Problem
Opioids are a common additive to neuraxial anesthesia. Opioid related side effects, such
as shivering, pruritis, nausea & vomiting, urinary retention, and respiratory depression are
undesirable and potentially detrimental to patients (Armstrong & Fernando, 2016). For these
reasons, opioid-free anesthesia (OFA) and opioid-sparing anesthesia (OSA) techniques have
become popular to lessen opioid administration throughout the perioperative period (Bohringer
et al., 2020). In the setting of neuraxial obstetric anesthesia, opioids reduce pain during delivery
and provide significant analgesia post-delivery (Armstrong & Fernando, 2016). Opioid-free and
opioid-sparing techniques offer satisfactory pain relief for obstetrical patients without opioid
related side effects, which improves the patient experience. Additionally, the uncomfortable side
effects associated with opioid use in neuraxial anesthesia negatively affect the patient (He et al.,
2020). Multimodal methods have improved surgical outcomes by reducing or eliminating the use
of opioids administered perioperatively (Boysen, Pappas, & Evans, 2018). Dexmedetomidine, an
alpha-2 agonist, is a powerful analgesic, anxiolytic, and antiemetic. The use of dexmedetomidine
lowers the need for opioids and diminishes side effects typically reported with opioid
administration (Bohringer et al., 2020).
Literature Review
Dexmedetomidine has multiple benefits. Dexmedetomidine does not negatively impact
cardiac, neurological, renal, and respiratory systems. When added to neuraxial anesthetics,

dexmedetomidine speeds time of sensory blockade onset, prolongs postoperative analgesia, and
lowers postoperative shivering when added to neuraxial anesthetics in obstetric patients (Solanki
& Goyal, 2015). The favorable side effect profile of dexmedetomidine makes it a powerful
adjunct for obstetric anesthesia.
In spinal anesthesia, dexmedetomidine prolongs sensory blockade and pain relief when
compared to opioid adjuncts or local anesthetics alone (Li et al., 2020; QI et al., 2016; Sun et al.,
2015). Additionally, dexmedetomidine decreases the incidence of shivering in parturient patients
(Nasseri et al., 2017). In epidural anesthesia, dexmedetomidine shortens the duration of labor
when compared to control group labor times and augments uterine contractions compared to
patients who were given opioid adjuncts. Patients who received neuraxial dexmedetomidine had
superior pain relief, decreased nausea & vomiting, and pruritis compared to patients who
received neuraxial opioids (Cheng et al., 2019; Jun et al., 2018).
Project Methods
The goal of this project was to review current medical literature regarding the use of
dexmedetomidine as a neuraxial adjunct in obstetrical patients. This project assessed anesthesia
providers’ current use of neuraxial dexmedetomidine, presented the findings of a literature
review, and assessed the probability of participants to change their dosing or use practices based
on literature findings. An educational PowerPoint presentation was designed to provide
practitioners with an in-depth understanding of dosing and administration of neuraxial
dexmedetomidine in this patient population.
A convenience sample was obtained from a regional medical center in the midwestern
United States. Participants included in the study included certified registered

nurse anesthetists and physician anesthesiologists employed by the hospital. The sample size
was 10 participants. All participants had survey access with a QR code on their personal devices.
This project was submitted to Southern Illinois University’s IRB committee for approval
and was granted exemption. The project is a quality improvement project and does not include
human subject experimentation. Research evaluated for this project is based on randomized
studies with no identifiable patient information.
Evaluation
This project was non-experimental in design. The project was aimed at determining the
participants’ current use of dexmedetomidine with a pre-presentation survey and the likelihood
of practice change following an educational PowerPoint presentation. Ten participants filled out
the pre-presentation survey while only eight participants completed the post-presentation survey.
The attrition rate was 20% due to provider availability.
Prior to the presentation, almost all anesthesia providers reported using opioids in both
spinals and epidurals for obstetric patients. Eighty percent (n=8) of providers reported using
fentanyl and 70% (n=7) reported using Duramorph in neuraxial anesthesia in the pre-presentation
questionnaire. All but 10% (n= 1) of pre-presentation survey responders reported the use of
dexmedetomidine in obstetric practice. Fifty percent (n= 5) reported dexmedetomidine use in
spinal anesthesia, 20% (n= 2) in epidural anesthesia, and 10% (n= 1) use in CSE technique. Postpresentation data revealed, 62.5% (n=5) will consider the use of dexmedetomidine in spinal
anesthesia, 37.5% (n= 3) will consider use in epidural anesthesia, and 12.5% (n= 1) for CSE
anesthesia moving forward in their practice.
The evidence provided effectively educated participants on the advantages of
incorporating dexmedetomidine into obstetric anesthesia practices. Pre-presentation, 30% (n= 3)

of the sample size reported opioid-free pain control as the greatest perceived benefit of
dexmedetomidine use, while 60% (n= 6) reported a lack of opioid side effects as the greatest
benefit. Thirty percent (n=3) mentioned a prolonged motor & sensory blockade as a benefit to
dexmedetomidine use and only 10% (n= 1) mentioned decreased shivering.
The presentation proved successful in increasing provider knowledge of potential side
effects of the medication. Post-presentation, 20% (n= 4) selected prolonged motor & sensory
blockade as the greatest benefit of dexmedetomidine use and 27.5% (n= 3) selected decreased
shivering. In the pre-presentation survey, 80% (n= 8) of providers reported hypotension &
bradycardia as the most noticeable side effect of neuraxial dexmedetomidine; comparatively,
100% (n= 8) of participants selected hypotension & bradycardia as the most common side effects
of neuraxial dexmedetomidine, demonstrating an increase in knowledge following the
presentation.
The educational in-service increased provider confidence with dexmedetomidine
administration. Pre-presentation, 30% (n= 3) of participants responded they were very confident
in their use of dexmedetomidine, while 20% (n= 2) were extremely confident, and 30% (n= 3)
reported feeling not confident. Following the presentation, 62.5% (n= 5) of providers reported
feeling extremely confident, 25% (n= 2) felt very confident, and 12.5% (n= 1) felt somewhat
confident; no providers reported feeling not confident with dexmedetomidine dosing after the
presentation, which determined the presentation provided efficacious education to obstetric
anesthesia providers.
There are several limitations to this research. The data included in this literature review
was primarily gathered in Eastern countries. Parturients on average were about 2 cm shorter and
a little over 20 kg lighter than parturients from the United States (Driscoll & Gregory 2020).

Higher doses of dexmedetomidine may be required to accommodate for a larger patient size,
skewing this project’s dosing recommendations. All studies utilized dexmedetomidine as the
independent variable, while keeping local anesthetic doses constant. Using a dexmedetomidine
dose with varying doses of local anesthetics may provide valuable information on how to
appropriate titrate dexmedetomidine in neuraxial anesthesia based on patient height.
Impact on Practice
The evidence supporting the efficacy of dexmedetomidine as a powerful neuraxial
adjunct is overwhelming. The literature search revealed dexmedetomidine can provide
significant pain relief in obstetric patients presenting for spinal or epidural anesthesia.
Dexmedetomidine can be administered without the untoward opioid-related side effects, and at
appropriate doses, side effects due to dexmedetomidine are unlikely to occur. Neuraxial
dexmedetomidine has the potential to reduce or even replace opioids in neuraxial anesthetics for
parturient patients. Dexmedetomidine has significant potential for conquering the quest for
effective OFA and OSA techniques.
Conclusion
The negative implications of opioid use have created a demand for opioid-free or opioidsparing pain management (Falières, 2020). Dexmedetomidine is a unique adjunct medication
providing desirable clinical benefits, such as powerful analgesia and anxiolysis, without negative
side effects (Bohringer et al., 2020). These characteristics make dexmedetomidine an ideal
adjunct to local anesthetics used in neuraxial analgesia and anesthesia for parturients.
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